Nasdaq
$3.98▲ 5.85%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $33.2MShares out 8.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 1d agoPre-market26.10.23 19:006-KKey event#●●●#●●●
Evaxion A/SBullish
Evaxion announced positive three-year follow-up data from its phase 2 trial of the personalized cancer vaccine EVX-01, demonstrating 89% vaccine target precision and sustained T-cell and clinical responses. Patients maintained clinical responses observed at the two-year mark with no tumor progression through the third year, and the company maintains a cash runway extending into the second half of 2027.…more
$3.98+5.85%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoPre-market26.10.19 19:006-KKey event
Evaxion A/S
Evaxion announced that all patients in the phase 2 trial of its personalized cancer vaccine, EVX-01, maintained clinical responses at the three-year follow-up with no observed tumor progression. These findings, which strengthen the company's data package for potential partnership discussions, will be presented at the ESMO 2026 Congress on October 24.…more
$3.98+5.85%vs prev closeView filingShare - 10.2Pre-market26.10.02 22:056-KKey event
Evaxion A/S
Evaxion will present new immune data from the phase 2 trial of its personalized cancer vaccine, EVX-01, at the SITC 2026 Annual Meeting held from November 4-8, 2026. The presentation will cover systemic immunomodulatory effects and insights into the vaccine's durability and efficacy as both a combination and stand-alone therapy.…more
$3.98+5.85%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoOvernight26.10.23 15:00#●●●#●●●#●●●
Evaxion Reports Positive 3-Year Data for Personalized Cancer Vaccine EVX-01…more
Evaxion announced that its personalized cancer vaccine EVX-01 demonstrated sustained immune responses and clinical stability in advanced melanoma patients at a three-year follow-up. While the results are promising, the company remains in the clinical development stage and requires further validation for commercialization.…more
$3.98+5.85%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 5d agoOvernight26.10.19 16:00
●●●●●●●● ●●●●● ●●●●●●
Evaxion announced that all patients in its phase 2 trial for the personalized cancer vaccine EVX-01 maintained clinical responses at the three-year follow-up mark. While these results support the potential for future partnerships, the company remains in the clinical development stage without commercial approval.…more
$3.98+5.85%vs prev close - 10.2Pre-market26.10.02 22:00
●●●●●●●● ●●●●● ●●●●●●
Evaxion will present new immune data from its phase 2 trial of the AI-designed cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The presentation will highlight systemic immunomodulatory effects beyond vaccine-specific T-cell responses.…more
$3.98+5.85%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report